LepinEJZhangQZhangX. Phosphorylated S6 ribosomal protein: A novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant2006; 6: 1560–1571.
3.
LieJT. Vasculopathy in the antiphospholipid syndrome: Thrombosis or vasculitis, or both?. J Rheumatol1989; 16: 713–715.
4.
HughsonMDMcCartyGABrumbackRA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol1995; 26: 716–724.
5.
NochyDDaugasEDrozD. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol1999; 10: 507–518.
6.
DaugasENochyDHuongDL. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol2002; 13: 42–52.
7.
TektonidouMGSotsiouFNakopoulouLVlachoyiannopoulosPGMoutsopoulosHM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome. Arthritis Rheum2004; 50: 2569–2579.
8.
CanaudGBienaiméFNoëlLH. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant2010; 10: 2051–2060.
9.
CanaudGBienaiméFTabarinF. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med2014; 371: 303–312.
10.
GalloRPadureanAJayaramanT. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation1999; 99: 2164–2170.
11.
CanaudGBienaiméFViauA. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med2013; 19: 1288–1296.
LammingDWYeLKatajistoP. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science2012; 335: 1638–1643.
14.
CanaudGKnebelmannBHarrisPC. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?. Am J Transplant2010; 10: 1701–1706.
15.
MeroniPLBorghiMORaschiETedescoF. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol2011; 7: 330–339.
16.
GiannakopoulosBKrilisSA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med2013; 368: 1033–1044.
17.
BerchtoldDPiccolisMChiaruttiniN. Plasma membrane stress induces relocalization of Slm proteins and activation of TORC2 to promote sphingolipid synthesis. Nat Cell Biol2012; 14: 542–547.
18.
AllenKLHamikAJainMKMcCraeKR. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood2011; 117: 6383–6391.
19.
AllenKLFonsecaFVBetapudiVWillardBZhangJMcCraeKR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood2012; 119: 884–893.
CanaudGKamarNAnglicheauD. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant2013; 13: 2179–2185.
22.
RossR. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature1993; 362: 801–809.
23.
PeiróCRedondoJRodríguez-MartínezMAAnguloJMarínJSánchez-FerrerCF. Influence of endothelium on cultured vascular smooth muscle cell proliferation. Hypertension1995; 25: 748–751.
24.
MilliatFFrancoisAIsoirM. Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: Implication in radiation-induced vascular damages. Am J Pathol2006; 169: 1484–1495.
25.
FernsGARainesEWSprugelKHMotaniASReidyMARossR. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science1991; 253: 1129–1132.
26.
GalvaniSAugéNCaliseD. HLA class I antibodies provoke graft arteriosclerosis in human arteries transplanted into SCID/beige mice. Am J Transplant2009; 9: 2607–2614.
27.
AmanoJIshiyamaSNishikawaT. Proliferation of smooth muscle cells in acute allograft vascular rejection. J Thorac Cardiovasc Surg1997; 113: 19–25.
28.
ShiCFeinbergMWZhangD. Donor MHC and adhesion molecules in transplant arteriosclerosis. J Clin Invest1999; 103: 469–474.
29.
GeraghtyJGStoltenbergRLSollingerHWHullettDA. Vascular smooth muscle cells and neointimal hyperplasia in chronic transplant rejection. Transplantation1996; 62: 502–509.
30.
GrimmPCNickersonPJefferyJ. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med2001; 345: 93–97.
31.
EisenHJTuzcuEMDorentR. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med2003; 349: 847–858.
32.
BoersemaMKattaKRienstraH. Local medial microenvironment directs phenotypic modulation of smooth muscle cells after experimental renal transplantation. Am J Transplant2012; 12: 1429–1440.
